Sugi Predict

Sugi Predict / Compounds / SCHEMBL9543379

SCHEMBL9543379

SCHEMBL9543379

CC(C)(C)OC(=O)N1C[C@@H](c2ccccc2)C[C@@H]1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTRA1 Q92743 1/20 0.60
▸ RORC P51449 3/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ NR1H2 P55055 2/20 0.43
▸ NR1H3 Q13133 2/20 0.43
▸ ELANE P08246 1/20 0.43
▸ TACR1 P25103 3/20 0.42
▸ HCRTR2 O43614 1/20 0.42
▸ UCHL1 P09936 1/20 0.41
▸ ABCB1 P08183 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ GPR119 Q8TDV5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5201925 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL1782234 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL5206918 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL1243964 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL2239296 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL5203691 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL205497 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL4195796 1.00 HTRA1 (0.60) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL1199659 0.90 HTRA1 (0.59) HTRA1RORCMEN1KMT2ANR1H2
SCHEMBL16972087 0.89 HTRA1 (0.50) HTRA1RORCNR1H2NR1H3ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-11 — — US disclosed
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-12-04 — — US disclosed
US-12486278-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-12-02 — — US disclosed
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-04-24 — — US disclosed
CN-114591212-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2025-01-28 — — CN disclosed
CN-119350433-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2025-01-24 — — CN disclosed
US-12195427-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2025-01-14 — — US disclosed
CN-112867706-B MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-11-15 — — CN disclosed
CN-118373875-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-07-23 — — CN disclosed
CN-117964683-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2024-05-03 — — CN disclosed
WO-2021113682-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
EP-3773555-A1 FACTOR XIIA INHIBITORS University of Leeds (GB) 2021-02-17 — — EP disclosed
US-20200361867-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2020-11-19 — — US disclosed
US-20200361867-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2020-11-19 — — US disclosed
US-10562850-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2020-02-18 — — US disclosed
US-10562850-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2020-02-18 — — US disclosed
WO-2019186164-A1 FACTOR XIIA INHIBITORS UNIVERSITY OF LEEDS (GB) 2019-10-03 — — WO disclosed
US-20180362458-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2018-12-20 — — US disclosed
EP-3355890-A1 HUMAN PLASMA KALLIKREIN INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2018-08-08 — — EP disclosed
WO-1993020099-A2 CCK AND/OR GASTRIN RECEPTOR LIGANDS FERRING B.V. (NL) 1993-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486278-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 HTRA1 1544/4885RORC 4838/4885MEN1 150/4885
US-20250368604-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 HTRA1 1555/4885RORC 4836/4885MEN1 157/4885
US-12195427-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 HTRA1 1555/4885RORC 4836/4885MEN1 157/4885
US-20250376443-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 HTRA1 1329/4885RORC 4818/4885MEN1 159/4885
US-20180362458-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 HTRA1 167/4885RORC 4484/4885MEN1 380/4885
US-10562850-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 HTRA1 167/4885RORC 4484/4885MEN1 380/4885
US-20200361867-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 HTRA1 167/4885RORC 4484/4885MEN1 380/4885
US-20250129020-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 HTRA1 1555/4885RORC 4836/4885MEN1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.